Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07903493
PHASE1

Phase Ia Study of MST-931 in Healthy Adult Subjects

Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

A Phase 1a, randomized, double-blind study of MST-931 in healthy participants. The purpose of this research is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous dose of MST-931 given to healthy participants. MST-931 is a monoclonal antibody.

Official title: A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MST-931 in Healthy Adult Subjects

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2026-11-30

Completion Date

2027-07-30

Last Updated

2026-11-03

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

MST-931

MST-931 is a proprietary monoclonal antibody developed by Mabsoft Therapeutics.

BIOLOGICAL

MST-931 Placebo

Matching placebo for MST-931

Locations (1)

Q-Pharm Pty Ltd

Herston, Queensland, Australia